Screening Methods to Discover the FDA-Approved Cancer Drug Encorafenib as Optimally Selective for Metallothionein Gene Loss Ovarian Cancer is a research paper published in Genes (2025). On theSindex it has a DataRank of 0. It has been cited 3 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health (NIH)
Grant: CA280626
National Institutes of Health (NIH)
Grant: CA256104
National Institutes of Health (NIH)
Grant: GM072643
National Institutes of Health (NIH)
Grant: GM1523862
National Institutes of Health (NIH)
Grant: 2019-198009
NIH HHS
Grant: S10 OD028663
NIGMS NIH HHS
Grant: P20 GM103499
NCI NIH HHS
Grant: P30 CA138313
NCI NIH HHS
Grant: DP2 CA280626
NCI NIH HHS
Grant: R03 CA256104
NIGMS NIH HHS
Grant: R25 GM072643
National Institutes of Health
Grant: 5R03CA256104-02
Combination Of Autophagy Selective Therapeutics (COAST) in Serous Ovarian Cancer
National Institutes of Health
Grant: 5P30CA138313-09
Medical University of South Carolina - Cancer Center Support Grant
National Institutes of Health
Grant: 5R25GM072643-18
MUSC Minority Student Development Program
National Institutes of Health
Grant: 4DP2CA280626-02
Tumor suppressor vulnerability conferred by aneuploid loss of haploinsufficient metallothionein genes
National Institutes of Health
Grant: 1S10OD028663-01
High-Content, High-Throughput Multi-Mode Imaging System
National Institutes of Health
Grant: 5P20GM103499-14
South Carolina IDeA Network of Biomedical Research Excellence
FWCI
1.82
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals